Open AccessPB1796 VALIDATION OF THE NEW PROGNOSTIC MODEL FOR PERIPHERAL T CELL LYMPHOMA OTHERWISE SPECIFIED DEVELOPED (PTCL‐NOS) BY THREE INSTITUTIONS
Author(s) -
SanchezGonzalez B.,
Novelli S.,
Jimenez S.A.,
GarciaPallarols F.,
Aspas G.,
Parraga I.G.,
Bento L.,
Corrochano M.,
Gimeno E.,
Gutierrez A.,
Briones J.,
Salar A.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000565688.75894.83
Subject(s) - medicine , peripheral t cell lymphoma , proportional hazards model , not otherwise specified , oncology , lymphoma , log rank test , t cell lymphoma , anaplastic large cell lymphoma , t cell , immunology , immune system
Background: Recently, a new prognostic model (T cell score) has been developed by the International T cell Project Network that identifies a group of peripheral T cell lymphoma otherwise specified (PTCL‐NOS) with very unfavorable outcomes. However, validation in independent cohorts remains as an essential step for models to gain widespread use. Aims: To validate T cell score, based on series of three hospitals from Spain. Furthermore, we explore the usefulness of T score in other subtypes of peripheral T cell lymphomas (PTCLs). Methods: T cell score is based on four covariates: serum albumin, ECOG‐performance status, stage and absolute neutrophil count (ANC). The T cell score is categorized in three risk groups as describe in the original paper. T cell score was applied retrospectively to series of all PTCLs in three Institutions. Validation was performed following the guidelines by Royston et al. Overall survival (OS) and progression‐free survival (PFS) were calculated using Kaplan‐Meier estimators, comparison between categories performed by log‐rank test and Cox PH regression, and the effect of covariates reported with 95% confidence interval (95 CI). Results: Between 1993 and 2018, 129 cases of PTCLs were identified for developing the prognostic model. The median age was 56 years (range 15‐91), 62 % of patients (pts) were male, and advanced stage disease was found in 77%. PTCLs subtypes: PTCL‐NOS 52 pts (40%), AITL 24 pts (26%), ALCL (ALK+)10 pts (8%), ALCL (ALK‐)17 pts (13%) and others 16 pts (12%). 77% of PTCL had advanced disease and 35% had ECOG ≥ 2. 71% of PTLC had albumin <35 g/l, 68% >6.5x109 cells/l. 84% of PTCLs were treated with anthracyclines. At a median follow‐up of 102 months, the median OS and PFS was 30 and 9.5 months, respectively. Three groups of PTCL‐NOS were separated for OS at low risk (LR, 6 patients, 11.5%, score 0), intermediate risk (IR, 29 patients, 55.8%, score 1–2), and high risk (HiR, 17 patients, 32.7%, score 3–4) (figure 1). The three risk groups had a 5‐year OS of 100%, 42 % [95 CI 24–61], and 6% [95 CI 0–17], respectively for patients at LR, IR and HiR respectively (p < 0.001) (Fig 1). The model also proved to be a potential tool for PFS; the 3‐year PFS was 33% [95 CI 0‐70], 38 % [95 CI 19‐56] and 0, respectively for patients at LR, IR and HiR respectively (p < 0.001; data not shown). Summary/Conclusion: Validation of the T cell score was performed in our series of PTCL‐NOS from three hospitals. T cell score clearly identified three risk groups for OS. Further validation of the T cell score in other independent series and analyze its potential application in other subtypes of PTCL, need to be performed.